×
0 0 0.0156551576238472 0.0130817070555436 0.0180141539781256 -0.00836371434698693 -0.00686253484880978 -0.00343126742440497
Stockreport

Ionis: Good Value With Non-Binary Upside [Seeking Alpha]

AKCEA THERAPEUTICS (AKCA)  More Company Research Source: Seeking Alpha
Last akcea therapeutics earnings: 11/6 04:05 pm Check Earnings Report
PDF Ionis: Good Value With Non-Binary UpsideSummaryIonis has a diverse pipeline that targets multiple disease categories.Its $500 mm annual revenue stems from licensing fees, milestones, and royalties.While Ionis itself is not a perfect candidate for the acquisition, its subsidiary, Akcea Therapeutics, is being groomed for an acquisition by rare disease players.Ionis' stock may double in 2018. [Read more]

IMPACT SNAPSHOT EVENT TIME: AKCA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS